James Berenson

661 total citations
23 papers, 564 citations indexed

About

James Berenson is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, James Berenson has authored 23 papers receiving a total of 564 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 13 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in James Berenson's work include Multiple Myeloma Research and Treatments (14 papers), Cancer Treatment and Pharmacology (5 papers) and Bone health and treatments (4 papers). James Berenson is often cited by papers focused on Multiple Myeloma Research and Treatments (14 papers), Cancer Treatment and Pharmacology (5 papers) and Bone health and treatments (4 papers). James Berenson collaborates with scholars based in United States, China and Greece. James Berenson's co-authors include Robert Vescio, Alan Lichtenstein, A. Fleishman, Jeremy M. G. Taylor, Matthew B. Rettig, John C. Reed, Yiping Tu, Judith Weisz, Stanisław Krajewski and Fei Xu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

James Berenson

23 papers receiving 550 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Berenson United States 11 310 250 207 122 100 23 564
R Bataille France 9 282 0.9× 372 1.5× 371 1.8× 219 1.8× 52 0.5× 13 707
Marielle Chiron France 12 299 1.0× 440 1.8× 321 1.6× 125 1.0× 81 0.8× 44 745
Josephine L. Klitgaard United States 7 178 0.6× 133 0.5× 108 0.5× 111 0.9× 171 1.7× 11 426
Sabikun Nahar United States 8 369 1.2× 312 1.2× 219 1.1× 79 0.6× 39 0.4× 21 649
Michael Voralia Canada 11 229 0.7× 268 1.1× 263 1.3× 149 1.2× 263 2.6× 25 681
Normann Steiner Austria 14 219 0.7× 191 0.8× 180 0.9× 54 0.4× 98 1.0× 55 471
Jennifer Macaluso United States 8 350 1.1× 170 0.7× 132 0.6× 75 0.6× 60 0.6× 9 539
Ricardo Parrondo United States 15 374 1.2× 255 1.0× 196 0.9× 86 0.7× 130 1.3× 75 698
Rosalind H. Gunby Italy 13 316 1.0× 180 0.7× 267 1.3× 57 0.5× 222 2.2× 17 683
Young Trieu Canada 13 561 1.8× 335 1.3× 525 2.5× 81 0.7× 93 0.9× 28 728

Countries citing papers authored by James Berenson

Since Specialization
Citations

This map shows the geographic impact of James Berenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Berenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Berenson more than expected).

Fields of papers citing papers by James Berenson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Berenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Berenson. The network helps show where James Berenson may publish in the future.

Co-authorship network of co-authors of James Berenson

This figure shows the co-authorship network connecting the top 25 collaborators of James Berenson. A scholar is included among the top collaborators of James Berenson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Berenson. James Berenson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moreau, Philippe, A. Keith Stewart, Meletios Α. Dimopoulos, et al.. (2019). PF612 ONCE‐WEEKLY (70 MG/M2) VERSUS TWICE‐WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA. HemaSphere. 3(S1). 260–260. 1 indexed citations
2.
Shvartsur, Anna, Devasis Chatterjee, Haiming Chen, et al.. (2015). A Bioinformatics Approach Revealed a Differential Expression of RKIP-Related Genes in Pre-Multiple Myeloma and Multiple Myeloma: Clinical Implications. Blood. 126(23). 5309–5309. 1 indexed citations
3.
Xiang, Jinbao, Zhuoqi Zhang, Chao Geng, et al.. (2015). Synthesis and Evaluation of 2‐Alkylthio‐4‐(N‐substituted sulfonamide)pyrimidine Hydroxamic Acids as Anti‐myeloma Agents. Chemical Biology & Drug Design. 87(3). 472–477. 4 indexed citations
4.
Berenson, James, Laura Stampleman, Alberto Bessudo, et al.. (2015). a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 126(23). 5383–5383. 4 indexed citations
5.
Hussein, Mohamed, Andrew R. Belch, Ralph V. Boccia, et al.. (2007). 146: Use of a novel organic arsenic (ZIO-101) after autotransplants for multiple myeloma. Biology of Blood and Marrow Transplantation. 13(2). 55–55. 1 indexed citations
6.
Berenson, James, Lakshmi Rajdev, & Michael S. Broder. (2006). Managing bone complications of solid tumors. Cancer Biology & Therapy. 5(9). 1086–1089. 27 indexed citations
7.
Berenson, James, Lakshmi Rajdev, & Michael S. Broder. (2006). Treatment strategies for skeletal complications of cancer. Cancer Biology & Therapy. 5(9). 1074–1077. 20 indexed citations
8.
Kornblau, Steven M., et al.. (2006). 479 POSTER ZIO-101: a new organic arsenic in advanced cancers. European Journal of Cancer Supplements. 4(12). 146–147. 1 indexed citations
9.
10.
Berenson, James, et al.. (2000). Phase II trial of zoledronate versus pamidronate in multiple myeloma and breast carcinoma patients with osteolytic lesions. Cancer. 88(12). 310215. 1 indexed citations
11.
Vescio, Robert & James Berenson. (1999). AUTOLOGOUS TRANSPLANTATION. Hematology/Oncology Clinics of North America. 13(5). 969–986. 7 indexed citations
12.
Tasaka, Taizo, Hiroya Asou, Reinhold Munker, et al.. (1998). Methylation of the p16INK4A gene in multiple myeloma. British Journal of Haematology. 101(3). 558–564. 45 indexed citations
13.
Thompson, Alexis A., Lori Kunkel, James Berenson, et al.. (1997). Aberrations of the B-Cell Receptor B29 (CD79b) Gene in Chronic Lymphocytic Leukemia. Blood. 90(4). 1387–1394. 11 indexed citations
14.
Thompson, Alexis A., Lori Kunkel, James Berenson, et al.. (1997). Aberrations of the B-Cell Receptor B29 (CD79b) Gene in Chronic Lymphocytic Leukemia. Blood. 90(4). 1387–1394. 71 indexed citations
15.
Schiller, Gary J., Stephen D. Nimer, Robert Vescio, et al.. (1994). Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma.. PubMed. 14(1). 131–6. 17 indexed citations
16.
Schiller, Gary J., Lisa Rosen, Robert Vescio, et al.. (1994). Threshold dose of autologous CD34-positive peripheral blood progenitor cells required for engraftment after myeloablative treatment for multiple myeloma. 1. 207. 4 indexed citations
17.
Lichtenstein, Alan, James Berenson, Joseph Gera, et al.. (1990). Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes.. PubMed. 50(22). 7364–70. 53 indexed citations
18.
Tu, Yiping, Fei Xu, A. Fleishman, et al.. (1990). BCL-X expression in multiple myeloma: possible indicator of chemoresistance.. Dialnet (Universidad de la Rioja). 58(2). 256–62. 201 indexed citations
19.
Berenson, James, et al.. (1990). Oncogenes in multiple myeloma: point mutation of N-ras.. PubMed. 5(11). 1659–63. 38 indexed citations
20.
Berenson, James & A. V. Lichtenstein. (1989). Clonal rearrangement of the beta-T cell receptor gene in multiple myeloma.. PubMed. 3(2). 133–6. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R Bataille Breakdown of academic impact, for papers by Marielle Chiron Breakdown of academic impact, for papers by Josephine L. Klitgaard Breakdown of academic impact, for papers by Sabikun Nahar Breakdown of academic impact, for papers by Michael Voralia Breakdown of academic impact, for papers by Normann Steiner Breakdown of academic impact, for papers by Jennifer Macaluso Breakdown of academic impact, for papers by Ricardo Parrondo Breakdown of academic impact, for papers by Rosalind H. Gunby Breakdown of academic impact, for papers by Young Trieu
Rankless by CCL
2026